Compare ACLX & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACLX | CSAN |
|---|---|---|
| Founded | 2015 | 1936 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | 2022 | N/A |
| Metric | ACLX | CSAN |
|---|---|---|
| Price | $66.63 | $3.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 2 |
| Target Price | ★ $113.75 | $4.75 |
| AVG Volume (30 Days) | 890.8K | ★ 2.4M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $35,898,000.00 | ★ $7,988,294,917.00 |
| Revenue This Year | N/A | $270.61 |
| Revenue Next Year | $293.08 | $0.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.13 |
| 52 Week Low | $47.86 | $3.80 |
| 52 Week High | $94.07 | $6.25 |
| Indicator | ACLX | CSAN |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 37.71 |
| Support Level | $63.33 | $3.93 |
| Resistance Level | $66.83 | $4.04 |
| Average True Range (ATR) | 2.27 | 0.12 |
| MACD | 0.85 | 0.02 |
| Stochastic Oscillator | 93.96 | 34.69 |
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.